As European Member States continue to evaluate the feasibility of population-based prostate cancer (PCa) screening, a landmark study published in the Journal of Personalized Medicine remains a critical roadmap of the obstacles ahead.
The paper, titled "Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey," features prominent leadership from WONCA Europe, including President-elect Thomas Frese, former Treasurer Josep M. Vilaseca, and Past President Shlomo Vinker.
Originally published in 2024, the study serves as a cornerstone of the PRAISE-U project. This multi-national initiative, which concludes its primary phase this month (April 2026), aligns with European Commission recommendations to explore organized, risk-based screening as a superior alternative to the "one-size-fits-all" approach.
High Support, Significant Hurdles
Drawing on 410 responses from 55 countries, the survey utilized the "Barriers to Effective Screening Tool" (BEST) to map the landscape of early detection. While 70% of all respondents supported the implementation of population-based screening, the study revealed a significant "support gap" between specialties:
-
Patient representatives (88%) and Urologists (79%) showed the strongest backing.
-
General Practitioners (42%) and Policy stakeholders (52%) expressed more caution, citing concerns over cost-effectiveness and the potential for overdiagnosis.
The "Big Three" Barriers
The research identified three primary obstacles preventing the transition from "opportunistic" testing—currently prevalent in 69% of regions—to organized national programs:
-
Lack of Political Support: Ranked as the #1 barrier globally. Respondents noted that without government prioritization and medical society consensus, formal programs cannot take root.
-
Resource Limitations: Specifically regarding the availability of MRI technology and clinical staffing. Recent 2026 data presented at the EAU Congress suggests that shorter, 10-minute MRI protocols and AI integration may soon help mitigate these costs.
-
Inadequate Participation & Promotion: Highlighting the difficulty of engaging the target population. Current European pilots report participation rates as low as 40%, emphasizing the need for better public promotion.
The Path Forward: A Risk-Based Approach
The authors—including the WONCA Europe leadership—emphasize a shift toward a "smart screening" or risk-adapted strategy. This moves the focus away from older PSA-only models and toward a pathway involving:
-
Awareness Campaigns: Educating both the public and GPs on the benefits of modern risk-stratification.
-
Integrated IT Systems: Developing compatible national electronic health records to ensure seamless follow-up.
-
European Guidelines: Establishing clear, unified protocols to build policymaker confidence across the EU.
Implications for Primary Care
For the WONCA Europe community, the study underscores the pivotal role of the GP as the "gatekeeper" of healthcare. The lower support levels among primary care physicians highlight a need for continued dialogue regarding how new technologies, such as multiparametric MRI (mpMRI) and risk calculators, can reduce the historical risks of overdiagnosis and overtreatment.
"Successful implementation is complex; it requires political and medical society support, operational resources, and the development of robust legal frameworks," the study concludes.
Full Citation: Beyer, K., et al. (2024). Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey. J. Pers. Med. 14(7), 751. https://doi.org/10.3390/jpm14070751